Skip to main content
. 2014 Apr 30;15(5):7500–7512. doi: 10.3390/ijms15057500

Table 3.

The American Association for the Study of Liver Diseases’ (AASLD) recommendations for the 12-week treatment of HCV genotype 1 infection.

Treatment-naive patients eligible to receive interferon Treatment-naive patients ineligible to receive interferon
sofosbuvir (400 mg) daily sofosbuvir (400 mg) daily
weight-based ribavirin daily simeprevir (150 mg) daily
peginterferon on a weekly basis with/without weight-based ribavirin